[go: up one dir, main page]

WO2019098763A3 - 알파-시누클레인에 대한 항체 및 그 용도 - Google Patents

알파-시누클레인에 대한 항체 및 그 용도 Download PDF

Info

Publication number
WO2019098763A3
WO2019098763A3 PCT/KR2018/014123 KR2018014123W WO2019098763A3 WO 2019098763 A3 WO2019098763 A3 WO 2019098763A3 KR 2018014123 W KR2018014123 W KR 2018014123W WO 2019098763 A3 WO2019098763 A3 WO 2019098763A3
Authority
WO
WIPO (PCT)
Prior art keywords
synuclein
antibodies
aggregates
diagnosis
accumulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/014123
Other languages
English (en)
French (fr)
Other versions
WO2019098763A9 (ko
WO2019098763A2 (ko
Inventor
이상훈
유원규
안진형
안성원
정진원
이보라
김동인
성병제
손용규
김연주
엄재현
안세원
박영돈
염동훈
송대해
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABL Bio Inc
Original Assignee
ABL Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2018370279A priority Critical patent/AU2018370279B2/en
Priority to JP2020527742A priority patent/JP7173618B2/ja
Priority to CN201880074418.3A priority patent/CN111356701B/zh
Priority to CA3082559A priority patent/CA3082559A1/en
Priority to US16/759,937 priority patent/US20230279085A1/en
Priority to MX2020004674A priority patent/MX2020004674A/es
Priority to EP18879299.8A priority patent/EP3725802A4/en
Priority to BR112020009707-1A priority patent/BR112020009707A2/pt
Priority to EA202090961A priority patent/EA202090961A1/ru
Application filed by ABL Bio Inc filed Critical ABL Bio Inc
Publication of WO2019098763A2 publication Critical patent/WO2019098763A2/ko
Publication of WO2019098763A3 publication Critical patent/WO2019098763A3/ko
Publication of WO2019098763A9 publication Critical patent/WO2019098763A9/ko
Anticipated expiration legal-status Critical
Priority to MX2025011654A priority patent/MX2025011654A/es
Priority to AU2022252753A priority patent/AU2022252753B2/en
Priority to JP2022172107A priority patent/JP7610279B2/ja
Priority to AU2025226709A priority patent/AU2025226709A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 알파-시누클레인 응집체를 선호적으로 인식하는 항-알파-시누클레인 항체와, 상기 항-알파-시누클레인 항체를 이용하여 알파-시누클레인 응집체 축적으로 인한 다양한 질환 또는 이의 관련 증상질환의 검출, 진단 및 /또는 치료 또는 예방 용도에 관한 것이다.
PCT/KR2018/014123 2017-11-17 2018-11-16 알파-시누클레인에 대한 항체 및 그 용도 Ceased WO2019098763A2 (ko)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA202090961A EA202090961A1 (ru) 2018-06-21 2018-11-16 Антитела к -синуклеину и их применения
CN201880074418.3A CN111356701B (zh) 2017-11-17 2018-11-16 抗α-突触核蛋白抗体及其用途
BR112020009707-1A BR112020009707A2 (pt) 2017-11-17 2018-11-16 anticorpos para a-sinucleína e usos dos mesmos
US16/759,937 US20230279085A1 (en) 2017-11-17 2018-11-16 ANTIBODIES TO alpha-SYNUCLEIN AND USES THEREOF
MX2020004674A MX2020004674A (es) 2017-11-17 2018-11-16 Anticuerpos contra alfa-sinucleina y usos de los mismos.
EP18879299.8A EP3725802A4 (en) 2017-11-17 2018-11-16 Antibodies to alpha-synuclein and uses thereof
JP2020527742A JP7173618B2 (ja) 2017-11-17 2018-11-16 アルファ－シヌクレインに対する抗体およびその用途
AU2018370279A AU2018370279B2 (en) 2017-11-17 2018-11-16 Antibodies to a-synuclein and uses thereof
CA3082559A CA3082559A1 (en) 2017-11-17 2018-11-16 Antibodies to .alpha.-synuclein and uses thereof
MX2025011654A MX2025011654A (es) 2017-11-17 2020-07-13 Anticuerpos contra alfa sinucleina y usos de los mismos
AU2022252753A AU2022252753B2 (en) 2017-11-17 2022-10-12 ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
JP2022172107A JP7610279B2 (ja) 2017-11-17 2022-10-27 アルファ－シヌクレインに対する抗体およびその用途
AU2025226709A AU2025226709A1 (en) 2017-11-17 2025-09-03 ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762588018P 2017-11-17 2017-11-17
US62/588,018 2017-11-17
US201862687848P 2018-06-21 2018-06-21
US62/687,848 2018-06-21

Publications (3)

Publication Number Publication Date
WO2019098763A2 WO2019098763A2 (ko) 2019-05-23
WO2019098763A3 true WO2019098763A3 (ko) 2019-07-11
WO2019098763A9 WO2019098763A9 (ko) 2019-08-29

Family

ID=66537805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/014123 Ceased WO2019098763A2 (ko) 2017-11-17 2018-11-16 알파-시누클레인에 대한 항체 및 그 용도

Country Status (10)

Country Link
US (1) US20230279085A1 (ko)
EP (1) EP3725802A4 (ko)
JP (2) JP7173618B2 (ko)
KR (1) KR102508933B1 (ko)
CN (1) CN111356701B (ko)
AU (3) AU2018370279B2 (ko)
BR (1) BR112020009707A2 (ko)
CA (1) CA3082559A1 (ko)
MX (2) MX2020004674A (ko)
WO (1) WO2019098763A2 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
BR112021025086A2 (pt) * 2019-06-14 2022-01-25 Abl Bio Inc Anticorpo biespecífico contra a-syn/igfir e uso do mesmo
EP4229082A1 (en) * 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
MX2023013392A (es) * 2021-05-12 2024-02-15 Abl Bio Incorporated Anticuerpos para tratar alfa-sinucleinopatias.
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用
WO2024044709A2 (en) * 2022-08-24 2024-02-29 The Research Foundation For The State University Of New York Anti-monomethyl auristatin antibodies and antibody fragments
CN117607463B (zh) * 2024-01-23 2024-04-09 杭州华得森生物技术有限公司 一种循环肿瘤细胞egfr免疫显色检测试剂
CN120446488B (zh) * 2025-07-08 2025-09-12 杭州华得森生物技术有限公司 用于多重免疫检测的试剂盒及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104696A1 (en) * 2010-02-26 2011-09-01 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
WO2011107544A1 (en) * 2010-03-03 2011-09-09 Dr. Rentschler Holding Gmbh & Co. Kg Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
KR20140053974A (ko) * 2011-06-23 2014-05-08 바이오겐 아이덱 인터내셔널 뉴로사이언스 게엠베하 항-알파 시누클레인 결합 분자
KR20160010402A (ko) * 2013-02-28 2016-01-27 유나이티드 아랍에미리트 대학교 알파-시누클레인 항체와 그것의 용도
WO2017009312A1 (en) * 2015-07-13 2017-01-19 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
BR112019013953A2 (pt) * 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
KR102263812B1 (ko) * 2017-12-14 2021-06-14 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104696A1 (en) * 2010-02-26 2011-09-01 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
WO2011107544A1 (en) * 2010-03-03 2011-09-09 Dr. Rentschler Holding Gmbh & Co. Kg Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
KR20140053974A (ko) * 2011-06-23 2014-05-08 바이오겐 아이덱 인터내셔널 뉴로사이언스 게엠베하 항-알파 시누클레인 결합 분자
KR20160010402A (ko) * 2013-02-28 2016-01-27 유나이티드 아랍에미리트 대학교 알파-시누클레인 항체와 그것의 용도
WO2017009312A1 (en) * 2015-07-13 2017-01-19 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Also Published As

Publication number Publication date
JP2023017837A (ja) 2023-02-07
AU2025226709A1 (en) 2025-09-25
JP7173618B2 (ja) 2022-11-16
MX2025011654A (es) 2025-11-03
AU2018370279A1 (en) 2020-05-28
CN111356701A (zh) 2020-06-30
EP3725802A2 (en) 2020-10-21
US20230279085A1 (en) 2023-09-07
AU2022252753B2 (en) 2025-06-05
JP2021503288A (ja) 2021-02-12
KR20190057004A (ko) 2019-05-27
WO2019098763A9 (ko) 2019-08-29
AU2022252753A1 (en) 2023-01-19
CA3082559A1 (en) 2019-05-23
CN111356701B (zh) 2023-11-21
MX2020004674A (es) 2020-08-13
WO2019098763A2 (ko) 2019-05-23
KR102508933B1 (ko) 2023-03-13
AU2018370279B2 (en) 2022-11-03
BR112020009707A2 (pt) 2020-10-13
EP3725802A4 (en) 2021-08-11
JP7610279B2 (ja) 2025-01-08

Similar Documents

Publication Publication Date Title
WO2019098763A3 (ko) 알파-시누클레인에 대한 항체 및 그 용도
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP4414385A3 (en) Polyomavirus neutralizing antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
HK1257747A1 (zh) 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
WO2014058924A3 (en) Antibodies recognizing alpha-synuclein
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2017181079A3 (en) Methods for monitoring and treating cancer
WO2015164392A3 (en) Novel antii-rnf43 antibodies and methods of use
WO2019177883A3 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MX383376B (es) Derivado de un anillo condensado y método de preparación, compuesto intermedio, composición farmacéutica y uso del mismo.
PH12017500032A1 (en) Improved a� protofibril binding antibodies
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
WO2015148984A3 (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
EA201791711A1 (ru) Антитела к транстиретину
HK1246810A1 (zh) Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
WO2015191892A3 (en) α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3082559

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020527742

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018370279

Country of ref document: AU

Date of ref document: 20181116

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18879299

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018879299

Country of ref document: EP

Effective date: 20200617

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020009707

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020009707

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200515